Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.49 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.44 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.44 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.44 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carbamic Acid SCHEMBL2175348 | 0.92 | TSHR (0.57) | TSHRNOTUMCYP2A6MAOAMAOB | |
| Acetamide SCHEMBL5312159 | 0.90 | TSHR (0.55) | TSHRNOTUMCYP2A6MAOAMAOB | |
| Carbamic Acid SCHEMBL9011736 | 0.87 | TSHR (0.65) | TSHRNOTUMCYP2A6MAOAMAOB | |
| Propionamide SCHEMBL28815857 | 0.84 | TSHR (0.48) | TSHRNOTUMCYP2A6MAOAMAOB | |
| SCHEMBL8948535 | 0.84 | TSHR (0.48) | TSHRNOTUMCYP2A6MAOAMAOB | |
| Hydrazine SCHEMBL2172540 | 0.83 | TSHR (0.75) | TSHRCYP2A6MAOAMAOBMAPT | |
| Hydrogen Peroxide SCHEMBL9391015 | 0.83 | TSHR (0.75) | TSHRCYP2A6MAOAMAOBSMN1; SMN2 | |
| SCHEMBL9662 | 0.83 | — | — | |
| SCHEMBL451157 | 0.83 | TSHR (0.86) | TSHRCYP2A6MAOAMAOBMAPT | |
| SCHEMBL29354295 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070238895-A1 | N-protected aminoindanes and methods of their preparation | TEVA PHARMACEUTICALS USA, INC. | 2007-10-11 | — | — | US | claimed |
| WO-2007056455-A2 | N-PROTECTED AMINOINDANES AND METHODS OF THEIR PREPARATION | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-05-18 | — | — | WO | claimed |
| CN-105061350-B | The sphingosine 1-phosphate receptor modulators and Chiral Synthesis of selectivity | 赛尔基因第二国际有限公司 | 2018-05-29 | — | — | CN | disclosed |
| CN-102753022-B | Selective heterocyclic sphingosine 1-phosphate receptor modulators | RECEPTOS, INC. (US) | 2016-04-20 | — | — | CN | disclosed |
| CN-105130922-A | SELECTIVE HETEROCYCLIC SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS | RECEPTOS INC | 2015-12-09 | — | — | CN | disclosed |
| CN-105061350-A | Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis | RECEPTOS INC | 2015-11-18 | — | — | CN | disclosed |
| CN-102762100-B | Selective sphingosine-1-phosphate receptor modulators and chiral synthesis methods | RECEPTOS INC | 2015-07-01 | — | — | CN | disclosed |
| US-20070238895-A1 | N-protected aminoindanes and methods of their preparation | TEVA PHARMACEUTICALS USA, INC. | 2007-10-11 | — | — | US | disclosed |
| WO-2007056455-A2 | N-PROTECTED AMINOINDANES AND METHODS OF THEIR PREPARATION | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238895-A1 | N-protected aminoindanes and methods of their preparation | PNMT, HNMT, NLN | TSHR 3685/4885NOTUM 902/4885CYP2A6 1225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.